Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SLS
stocks logo

SLS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.073
-8.34%
--
--
-0.073
+4.76%
--
--
-0.077
+9.53%
Estimates Revision
The market is revising No Change the revenue expectations for SELLAS Life Sciences Group, Inc. (SLS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -8.90%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-8.90%
In Past 3 Month
Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is 7.25 USD with a low forecast of 7.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is 7.25 USD with a low forecast of 7.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.740
sliders
Low
7.00
Averages
7.25
High
7.50
Current: 1.740
sliders
Low
7.00
Averages
7.25
High
7.50
Maxim
Maxim
Buy
maintain
$4 -> $7
2025-07-16
Reason
Maxim
Maxim
Price Target
$4 -> $7
2025-07-16
maintain
Buy
Reason
Maxim raised the firm's price target on Sellas Life Sciences to $7 from $4 and keeps a Buy rating on the shares. Shares have risen about 90% year-to-date as the company continues to execute across its Acute Myeloid Leukemia, or AML, programs, the analyst tells investors in a research note. Maxim further cites the company's galinpepimut-S in Phase 3 and yesterday's positive SLS009 data hitting all its endpoints, adding that its higher price target factors in SLS009 in first-line AML as a potential triplet combination with venetoclax/azacitidine.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sellas Life Sciences Group Inc (SLS.O) is -4.97, compared to its 5-year average forward P/E of -3.51. For a more detailed relative valuation and DCF analysis to assess Sellas Life Sciences Group Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.51
Current PE
-4.97
Overvalued PE
-1.33
Undervalued PE
-5.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.09
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.33
Undervalued EV/EBITDA
-0.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.57
Current PS
0.00
Overvalued PS
32.87
Undervalued PS
-11.74
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 581.12% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 581.12% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SLS News & Events

Events Timeline

(ET)
2025-11-12
16:56:30
Sellas Life Sciences Announces Q3 EPS of 6 Cents, Below Consensus Estimate of 8 Cents
select
2025-10-27 (ET)
2025-10-27
08:37:56
Sellas Life Sciences Reports $31M Raised Through Warrant Exercise
select
2025-10-13 (ET)
2025-10-13
08:14:50
Sellas Life Sciences to Showcase Preclinical In Vivo Data for SLS009
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:13 AMNewsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six patients treated across the cohorts showing no safety or tolerability issues, indicating strong tolerability of the therapy for relapsed blood cancers.
  • Dose Advancement: The company is now advancing to Cohort 4, where patients will receive a dose of 10μg/kg/day, which is believed to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and driving further clinical trial progress.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide critical clinical data updates in the first quarter of 2026, further boosting investor confidence.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, demonstrating potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
9.0
01:42 AMPRnewswire
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six participants showing no safety or tolerability issues at progressively higher doses, indicating the therapy's potential in treating relapsed blood cancers.
  • Dose Advancement: The company has moved into Cohort 4, where patients will receive a dose of 10μg/kg/day, which is expected to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and improving patient prognosis.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide a more comprehensive clinical update in the first quarter of 2026.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, showcasing innovative potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
9.5
11-13NASDAQ.COM
After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports

  • MacroGenics Earnings Report: MacroGenics, Inc. saw a 10.2% increase in after-hours trading, reporting a third-quarter net income of $16.8 million, down from $56.3 million year-over-year, with revenue falling to $72.8 million.

  • SELLAS Life Sciences Update: SELLAS Life Sciences Group, Inc. rose 9.4% after narrowing its quarterly net loss to $6.8 million, with cash and equivalents reported at approximately $44.3 million as of September 30, 2025.

  • KORU Medical Systems Performance: KORU Medical Systems, Inc. gained 8.47% after reporting a narrower net loss of $0.8 million and a 27.2% revenue increase to $10.4 million, while raising its full-year revenue guidance.

  • Wave Life Sciences Results: Wave Life Sciences Ltd. increased by 5.68% after reporting a third-quarter net loss of $53.9 million, an improvement from the previous year, with revenue of $7.6 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sellas Life Sciences Group Inc (SLS) stock price today?

The current price of SLS is 1.74 USD — it has increased 12.99 % in the last trading day.

arrow icon

What is Sellas Life Sciences Group Inc (SLS)'s business?

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

arrow icon

What is the price predicton of SLS Stock?

Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is 7.25 USD with a low forecast of 7.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sellas Life Sciences Group Inc (SLS)'s revenue for the last quarter?

Sellas Life Sciences Group Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Sellas Life Sciences Group Inc (SLS)'s earnings per share (EPS) for the last quarter?

Sellas Life Sciences Group Inc. EPS for the last quarter amounts to -0.06 USD, decreased -40.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sellas Life Sciences Group Inc (SLS)'s fundamentals?

The market is revising No Change the revenue expectations for SELLAS Life Sciences Group, Inc. (SLS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -8.90%.
arrow icon

How many employees does Sellas Life Sciences Group Inc (SLS). have?

Sellas Life Sciences Group Inc (SLS) has 15 emplpoyees as of December 05 2025.

arrow icon

What is Sellas Life Sciences Group Inc (SLS) market cap?

Today SLS has the market capitalization of 247.85M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free